

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

**Cosentyx Clinical Prior Authorization Criteria Revision Scheduled for
November 22**

Background:

HHSC will implement revisions to the clinical prior authorization criteria for Cosentyx to comply with the recent Food and Drug Administration-approved age indications.

Key Details:

On November 22, HHSC will revise the age for Cosentyx, in the Cytokine and CAM Inhibitor prior authorization guide to 2 years and older for psoriatic arthritis.

The Cytokine and CAM Antagonists clinical prior authorization is optional for MCOs. MCOs that have implemented this clinical prior authorization must revise by November 22.